Performance of Research and Development Clause Samples
The 'Performance of Research and Development' clause defines the obligations and standards for conducting research and development activities under an agreement. It typically outlines the scope of work, timelines, milestones, and the responsibilities of each party involved in the R&D process. For example, it may specify the expected deliverables, reporting requirements, and criteria for evaluating progress. This clause ensures that both parties have a clear understanding of how R&D efforts will be managed and measured, thereby reducing misunderstandings and aligning expectations throughout the project.
Performance of Research and Development. The research and development activities to be carried out under this CRADA will be performed solely by the Parties identified on the Cover Page, unless specifically stated elsewhere in the Agreement. The CRADA PIs will be responsible for coordinating the scientific and technical conduct of this project on behalf of their employers. Any Collaborator employees who will work at ICD facilities will be required to sign a Guest Researcher or Special Volunteer Agreement appropriately modified in view of the terms of this CRADA.
Performance of Research and Development. The research and development activities to be carried out under this CRADA will be performed by the Parties identified on the Cover Page, as well as ICD’s contractors or grantees as described in the Research Plan. However, ICD’s contractors or grantees are not Parties to the CRADA, and this CRADA does not grant to Collaborator any rights to Inventions made by ICD’s contractors or grantees. The CRADA PIs will be responsible for coordinating the scientific and technical conduct of this project on behalf of their employers. Any Collaborator employees who will work at ICD facilities will be required to sign a Guest Researcher or Special Volunteer Agreement appropriately modified in view of the terms of this CRADA.
Performance of Research and Development. VA Employees and Collaborator shall carry out the collaborative research as described in the SOW and in accordance with applicable Federal laws, regulations and VA policies and procedures. Each Party agrees to comply with, and to ensure that its contractors and agents comply with, applicable statutes, Executive Orders, and VA regulations relating to research on human subjects including but not limited to 38 C.F.R. Parts 16 and 17 and 21 C.F.R. Parts 50, 56, and 312 as applicable to the research described in the SOW. Such regulations may include the Standards for Privacy of Individually Identifiable Health Information and the Security Standards for the Protection of Electronic Protected Health Information (45 C.F.R. Parts 160 and 164), as well as those set forth in VA’s security directives.
Performance of Research and Development. Each Party agrees to comply with, and to ensure that its contractors and agents comply with the Protocol, SOW, applicable Federal laws, VA policies, Executive Orders, and regulations including but not limited to 38 C.F.R. Parts 16 and 17, 21 C.F.R. Parts 50, 56, and 800-898 as applicable to the research described in the Protocol. Such regulations include, but are not limited to, the Standards for Privacy of Individually Identifiable Health Information and the Security Standards for the Protection of Electronic Protected Health Information (45 C.F.R. Parts 160 and 164), as well as those set forth in VA’s security directives.
Performance of Research and Development. The research and development activities to be carried out under this CRADA will be performed by the Parties in accordance with the Research Plan identified on the Cover Page, as well as and by ICD’s contractors or grantees as described in the Research Plan. However, ICD’s contractors or grantees are not Parties to the CRADA, and this CRADA does not grant to Collaborator any rights to Inventions made by ICD’s contractors or grantees. Notwithstanding the forgoing, ICD will include provisions granting Collaborator those rights described in CTEP’s Intellectual Property Option to Collaborators in each Funding Agreement for clinical studies conducted by an extramural Clinical Investigator(web site: ▇▇▇▇://▇▇▇▇.▇▇▇▇▇▇.▇▇▇/industry). The CRADA PIs will be responsible for coordinating the scientific and technical conduct of this project on behalf of their employers. Any Collaborator employees who will work at ICD facilities will be required to sign a Guest Researcher or Special Volunteer Agreement appropriately modified in view of the terms of this CRADA.
Performance of Research and Development. The research and development activities to be carried out under this CRADA will be performed solely by the Parties identified on the Cover Page, unless specifically stated elsewhere in the Agreement. The CRADA PIs will be responsible for coordinating the scientific and technical conduct of this project on behalf of their employers. Any Collaborator employees who will work at ICD facilities will be required to sign a Guest Researcher or Special Volunteer Agreement appropriately modified in view of the terms of this CRADA. Confidential Information will only be communicated by a Party to employees or individuals working on behalf of that Party who have a need for the Confidential Information in connection with the research and development activities to be carried out under this CRADA and who are under an obligation of confidentiality no less restrictive than in this Agreement.
Performance of Research and Development. VA Employees and Collaborator shall carry out the collaborative research as described in the SOW and in accordance with applicable Federal laws, regulations and VA policies and procedures. Each Party agrees to comply with, and to ensure that its contractors and agents comply with, applicable statutes, Executive Orders, and VA regulations applicable to the research described in the SOW.
Performance of Research and Development. The Joint Work Statement will be performed solely by the Parties identified on the Cover Page unless specifically stated elsewhere in this Agreement. The interim research goals in the Joint Work Statement are good faith guidelines. If events occur that require modification of these goals, then by mutual agreement the Parties can modify the goals by amendment.
Performance of Research and Development. The research and development activities to be carried out under this CRADA will be performed by the Parties identified on the Cover Page, as well as IC’s Grantees as described in the Research Plan. However, IC’s Grantees are not Parties to the CRADA, and this CRADA does not grant to Collaborator any rights to Inventions made by IC’s Grantees. IC will ensure that prior to a Clinical PHS ECT-CRADA Case Ref. No. DK#12-0424_MODEL ADOPTED December 8, 2010 rev August 2012 Research Site or any other Grantee (other than the DCC) commencing activities in connection with this CRADA, such Clinical Research Site or other Grantee has executed the Collaborator Agreement with Collaborator. IC will also ensure that prior to the DCC commencing activities in connection with this CRADA, the DCC has executed an agreement with the Collaborator mutually agreeable to IC, the DCC and the Collaborator (“DCC Agreement”). The NIH CRADA Extramural Investigator/Officer(s), CRADA Collaborator PI(s), and the Data Coordination Center will be responsible for coordinating the scientific and technical conduct of this project on behalf of their employers. IC will ensure that Clinical Research Sites are required to provide all Raw Data and Summary Data to the CRADA Collaborator upon Collaborator’s request to comply with regulatory reporting requirements (or as otherwise agreed in a Collaborator Agreement), and in any event at the completion of the Clinical Trial.
Performance of Research and Development. The research and development activities to be carried out under this CRADA will be performed by the Parties identified on the Cover Page, as well as IC’s contractors or grantees as described in the Research Plan (including the Clinical Research Sites and Clinical Investigators), in accordance with the terms and conditions of this CRADA and all applicable laws, rules and regulations. Notwithstanding that IC’s contractors or grantees are not Parties to the CRADA, and this CRADA does not grant to Collaborator any rights to Inventions made by IC’s contractors or grantees, IC agrees that its contractors and grantees (including the Clinical Research Sites and Clinical Investigators) will be required to comply with the Research Plan and Protocol; will use the Test Article, Placebo and Collaborator Materials in accordance with the Protocol and the terms and conditions under Paragraph 3.10 below, and will make available or otherwise provide access to all CRADA Data in accordance with Article 8 below. IC further agrees to notify Collaborator promptly upon becoming aware of any noncompliance with the foregoing and to discuss in good faith any action to be taken against its contractors and grantees in response to such noncompliance, including seeking any available remedies under any applicable law or in equity. The NIH CRADA Extramural Investigator/Officer(s) and CRADA Collaborator PI(s) will be responsible for coordinating the scientific and technical conduct of this project on behalf of their employers. Any Collaborator employees who will work at IC facilities will be required to sign a Guest Researcher or Special Volunteer Agreement appropriately modified in view of the terms of this CRADA. [*****] Raptor Pharmaceutical Corp. has requested confidential treatment of certain portions of this offer letter which have been omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934.